Skip to main content

Caroline Helwick

Medical Writer
Authored Items
Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals
Caroline Helwick
March 2016, Vol 9, Seventh Annual Payers' Guide in FDA Approvals, Payers' Guide
Searching for the Tipping Point in Drug Pricing
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Oncology Pipeline Full, and Not Just with Immunotherapies
Caroline Helwick, Wayne Kuznar
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology in FDA Approvals
Aetna Examines Impact of Site of Service on Chemotherapy Cost
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Researchers Dissect the Cost of Targeted Agents
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Bevacizumab Wins Cost-Effectiveness Contest in First-Line Metastatic Colorectal Cancer
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Will Necitumumab Be Cost-Effective?
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
UnitedHealthcare’s Episode-Based Payment Model Program Cuts Cost
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Bundling Payments: UnitedHealthcare Dips a Toe in the Water
Caroline Helwick
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Novel Rosacea Compound, Ivermectin Cream, Offers Unique Mechanism of Action
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Ivermectin Cream Will Contribute Much to the Treatment of Patients with Rosacea: Interview with Dr Zoe Draelos
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Addressing an Unmet Need in the Treatment of Patients with Papulopustular Rosacea: An Interview with Dr Linda Stein Gold
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Investigational Agent Clears Papulopustular Rosacea by Tackling an Underlying Cause
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Less May Be “More” with Zoledronic Acid
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Breast Cancer, Oncology
Novel Drug Classes Make News in Multiple Myeloma
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Multiple Myeloma, Oncology
Site of Service Influences Value
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
Value-Based Insurance Not Such an Easy Sell
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
What Makes a Treatment Clinically Meaningful?
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
ASCO Beginning to Address Value in Oncology
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
Ramucirumab Shows Survival Benefit in NSCLC
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Lung Cancer, Oncology
Anti–PD-1 Antibodies for NSCLC and Renal Carcinoma
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in FDA Approvals
Enthusiasm Sky High for Immunotherapy with Anti–PD-1 Agents in Cancer
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in FDA Approvals
Generic Docetaxel Increases Risk of Neutropenia, Costs
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
Financial Distress Experienced by 40% of Patients with Cancer
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
ASCO Workgroup Proposes Consolidated Payments
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
2014 Oncology Pipeline Looks Impressive
Caroline Helwick, Wayne Kuznar
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in FDA Approvals
Ibrutinib Outperforms Ofatumumab in Patients with Relapsed/Refractory CLL
Caroline Helwick
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology in Leukemia, Oncology
The Social Impact of Rosacea, Patterns of Care, and Associated Costs Featured at AAD 2014
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
AAD 2014 Highlights: Understanding Inflammation Markers and Treating Erythema in Rosacea
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Rosacea: A Multifaceted Skin Disorder
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Introduction to Rosacea: An Underrecognized and Undertreated Medical Condition
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
More Transplants Made Possible Through Haploidentical Donors
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Conference Highlights ASH
Rituximab Maintenance Extends Remission in Follicular Lymphoma, but Overall Survival Unaffected
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Lymphoma
PI3K Inhibitors Main Focus of Drug Pipeline for Lymphoma
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Lymphoma
Myeloma Drug Arsenal Expanding to New Classes
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Multiple Myeloma, Oncology
Lenalidomide Maintenance in Transplant-Eligible Myeloma Population Still Debated
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Multiple Myeloma, Oncology
FIRST Trial Shows Value for Continued Use of Lenalidomide in Transplant-Ineligible Patients with Newly Diagnosed Myeloma
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology in Multiple Myeloma, Oncology
Novel CAR-T Therapy Topped the News at ASH 2013
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Hematologists Urged to Reduce Unnecessary Tests/Procedures, and Costs to Improve Quality of Care
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Hematologists Often Ignore Treatment and Monitoring Recommendations
Caroline Helwick
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Cost and Drug Utilization Patterns Associated with the Management of Rosacea
Caroline Helwick
November/December 2013, Vol 6, No 9 in Practice Management
Cost and Drug Utilization Patterns Associated with the Management of Rosacea
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Skin Disorders the Number One Reason for Medical Visits in the United States
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Emerging Therapies for the Treatment of Rosacea
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
FDA Expected to Approve Surrogate End Point for Neoadjuvant Breast Cancer Trials
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue in Practice Management
Two Surveys Confirm Drug Shortages Are a Persistent Problem, Increasing Costs
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Routine Surveillance CT Costly, Unnecessary in Lymphoma in Remission
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Assessing the Value of New, Costly Radiation Therapies in Older Patients with Breast Cancer
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Can We Afford to Make Progress in Cancer Care?
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Do Financial Incentives Drive Physician Behavior?
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Off-Label Drug Use in Oncology Accounts for 18% of Spending
Caroline Helwick
August 2013 Vol 6, No 6 Special Issue
Cancer Drug Pipeline Is Bustling
Caroline Helwick, Wayne Kuznar
August 2013 Vol 6, No 6 Special Issue
Rosacea: A Misunderstood, Serious Medical Condition
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Current Therapies for the Management of Patients with Rosacea
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Redness in Rosacea: Still an Unmet Medical Need
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Face to Face with Rosacea
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Investing in Information Technology Pays Off: Meaningful Use Stage 1 Met by Majority of US Hospitals
Caroline Helwick
March/April 2013 Vol 6, No 2 in Practice Management, Technology
Payer Perspective: Reimbursement Obstacles Prevent Effective Treatment of Rosacea
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Rosacea Management: A Conversation with Dr Guy Webster
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Anti-Inflammatory–Dose Doxycycline Is Equally Effective in Men and Women with Rosacea
Caroline Helwick
Payer Perspectives in Dermatology in Dermatology
Oral Proteasome Inhibitor MLN9708 a News Maker at ASH 2012
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue in Multiple Myeloma, Oncology
Host Factors Important in Patients with Myeloma
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue in Multiple Myeloma, Oncology
New Data Demonstrate Overall Survival Benefit with Pomalidomide in Advanced Myeloma
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue in Multiple Myeloma, Oncology
Bendamustine plus Rituximab Noninferior to Standard Chemotherapy for Indolent Non-Hodgkin and Mantle-Cell Lymphomas
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue in Lymphoma
Rivaroxaban More Cost-Effective than Warfarin for Recurrent VTE Prevention
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Costs of Second-Line Metastatic Colorectal Cancer Treatments Compared
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Rasburicase Cost-Effective for Tumor Lysis Syndrome
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Faster Rituximab Infusion Lowers Cost
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Hematologic Drug Pipeline Is Bustling
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Azacitidine Reduces Transfusions and Costs for Patients with High-Risk MDS
Caroline Helwick
February 2013 Vol 6, No 1, Special Issue
Chemotherapy-Related Toxicity Adds to Economic Burden in Metastatic Breast Cancer
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Breast Cancer, Oncology
Pomalidomide Shows Strong Activity in Relapsed/Refractory Myeloma
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Multiple Myeloma, Oncology
Molecular Profiling Guiding Cancer Therapy
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Crizotinib Effective in Aggressive Pediatric Tumors
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in Pediatric Cancer, Oncology
The Oncology Drug Pipeline Robust with Novel Agents
Caroline Helwick, Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective in FDA Approvals
The Cost of Lung Cancer at the End of Life: Early Institution of Palliative Care Improves Survival
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Why Hasn’t Genomic Testing Changed the Landscape?
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Metastatic Colorectal Cancer: Prolonged Bevacizumab Improves Outcomes, New Targeted Therapies on the Horizon
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Is Biomarker Testing in NSCLC Cost-Effective?
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Patient Adherence Rises with Cost of Oral Cancer Drugs
Caroline Helwick
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Is Plerixafor Cost-Effective for Stem-Cell Mobilization?
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
Novel Oral B-Cell Receptor Inhibitor Very Effective in Chronic Lymphocytic Leukemia
Caroline Helwick, Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue in Leukemia, Oncology
VISTA Final Analysis Upholds Survival Benefit of Bortezomib at 5 Years
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue in Multiple Myeloma, Multiple Myeloma, Oncology
Maintenance Strategies in Elderly Patients with Myeloma Not Eligible for Transplant
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue in Multiple Myeloma, Multiple Myeloma, Oncology
Guidelines for Molecular/Cytogenetic Tests Can Eliminate Overordering, Reduce Costs
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
High Morbidity Burden Borne Years Later by Survivors of Transplant
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue in Conference Highlights ASH
Maintenance Rituximab May Be Unnecessary in FL
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue in Leukemia, Oncology
Radiologic Surveillance for Early-Stage Hodgkin Lymphoma an Unnecessary Expense?
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
A Large Study Sheds Light on the Cost of Managing NHL
Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
Hematologic Pipeline Abundant
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue
VTE Prophylaxis during Chemotherapy Cost-Effective
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue in Conference Highlights ASH
Next-Generation Proteasome Inhibitors Cause Less Peripheral Neuropathy
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue in Multiple Myeloma, Multiple Myeloma, Oncology
Genetic Profiles Linked to Hematologic Outcomes
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue in Conference Highlights ASH
Future Directions in Myeloma
Caroline Helwick, Caroline Helwick
February 2012 Vol 5, No 1, Special Issue in Multiple Myeloma, Multiple Myeloma, Oncology
Drug Shortages the “New” Old Problem: People Are (Finally) Talking
Caroline Helwick
November/December 2011, Vol4, No7 in Practice Management
Can Episode Payments Reduce Cost and Maintain Quality Cancer Care?
Caroline Helwick
July/August 2011, Vol 4, No 4
Value of Targeted Therapies in Patients Lacking a Molecular Target Questioned
Caroline Helwick
August 2011 Vol 4, No 4, Special Issue
Optimal Length of Treatment of Non-Hodgkin Lymphoma Debated
Caroline Helwick
August 2011 Vol 4, No 4, Special Issue in Lymphoma
Financial Incentives Encourage Patients to Choose Less Expensive Regimens
Caroline Helwick
August 2011 Vol 4, No 4, Special Issue
Novel Approaches to Therapy in the Oncology Pipeline
Caroline Helwick
August 2011 Vol 4, No 4, Special Issue in FDA Approvals
US Provider Practices Bracing for Change: New Survey Results
Caroline Helwick
Web Exclusives
Promising Oncology Drugs in the Pipeline
Caroline Helwick
Web Exclusives in FDA Approvals
Oncologists Cautioned About Use of ESAs
Caroline Helwick
Web Exclusives
Anticancer Drug Development Trends: Translational Medicine
Caroline Helwick
May 2008, Vol 1, No 4
Paying for Cancer Care: Economic Models Start to Emerge, Dovetailing Healthcare Reform
Caroline Helwick
April/May 2009, Vol 2, No 3 in Practice Management
NCCN Panel Debates the Economics of Cancer Care
Caroline Helwick
March/April 2010, Vol 3, No 2 in Conference Highlights NCCN
PET Scans Not Recommended for Most Patients with Breast Cancer: Potential New Controversy in Breast Cancer Testing
Caroline Helwick
March/April 2010, Vol 3, No 2 in Conference Highlights NCCN
Emerging Trends in Breast Cancer Management
Caroline Helwick
January/February 2010, Vol 3, No 1 in Practice Management
New Approaches to Treating HCV Infection
Caroline Helwick
May/June 2010, Vol 3, No 3 in Conference Highlights Digestive Disease Week
Last modified: March 14, 2014